Non-Hodgkin lymphoma (NHL) cell lines with down-regulated Pcdh10 expression were less sensitive to leukemia specific drugs including dexamathasone and methotrexate, while T-cell and B-cell lymphoma cell lines with Pcdh10 methylation or down-regulated expression showed doxorubicin resistance, providing new evidence for the selection of treatment plans (Narayan et al. 2013). The gene discussed is PCDH10; the disease is B-cell non-Hodgkin lymphoma.